Search 

invest

MNC pharmaceuticals company

Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, and fintech spaces. a16z has nearly $16.5B in assets under management across multiple funds, including the $1.4B Bio funds, the $865M Crypto funds, and the Cultural Leadership Fund.

a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, and who have domain expertise ranging from biology to crypto to distributed systems to security to marketplaces to financial services.

We aim to connect entrepreneurs, investors, executives, engineers, academics, industry experts, and others in the technology ecosystem. We have built a network of experts including technical and executive talent; top media and marketing resources; Fortune 500/Global 2000 companies; as well as other technology decision makers, influencers, and key opinion leaders. a16z uses this network as part of our commitment to help our portfolio companies grow their business, so our operating teams provide entrepreneurs with access to expertise and insights across the entire spectrum of company building.

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.

Health analytics

VC in Chicago

Arctoris, the world's first fully-automated drug discovery laboratory, provides a revolutionary service - delivering drug discovery data on demand to scientists in biotech, pharma and academia engaged in preclinical research. Thanks to end-to-end automation technologies, Arctoris enables scientists from anywhere in the world to conduct cutting-edge drug discovery research with just their ideas and an internet connection. This is the future of research.

Scientists using the Arctoris platform are able to step away from the laboratory and its time-consuming manual tasks and resume more valuable intellectual activities. Arctoris produces rich, reproducible and structured data, whilst removing the need to set-up and operate expensive laboratories - a compelling proposition for scientists of all industries. Arctoris raises the standard of research, making it faster, more cost-effective, and more reliable.

Get in contact to discuss how Arctoris can augment your research and accelerate your discovery.

We are a Europe-based oncology start-up developing an entirely novel class of orally available small molecules to address currently untreatable cancers. We wholly own a pipeline of molecules that are active via novel mechanisms in cancer and several other therapeutic areas.
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS) via a synthetic lethality mechanism. High ROS tumours are, in general, untreatable. This group of cancers includes KRAS- and MYC-mutation driven cancers, which comprise above 30% of all cancer cases. leading to more than 1 million deaths worldwide every year. Treatment options for this group of cancers are extremely limited. We expect that our lead compound will define a new treatment paradigm across existing cancer categories. We have robust biomarkers to drive clinical development and links to world leading cancer centres in Europe and Asia.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept. Our mission is to restore hope to patients and their families.

Our vision is: Curing cancer, pushing science to its limits and contributing to safe medical devices around the world!

As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less